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Summary A randomised trial of 367 patients with
acute myocardial infarction was performed
to determine whether an invasive strategy combining
thrombolysis with recombinant tissue-type plasminogen
activator (rTPA), heparin, and acetylsalicylic acid, and
immediate percutaneous transluminal coronary angioplasty
(PTCA) would be superior to a noninvasive strategy with
the same medical treatment but without immediate
angiography and PTCA. Intravenous infusion of 100 mg
rTPA was started within 5 h after onset of symptoms
(median 156 min). Angiography was performed 6-165 min
later in 180 out of 183 patients allocated to the invasive
strategy; 184 patients were allocated to the non-invasive
strategy. Immediate PTCA reduced the percentage stenosis
of the infarct-related segment, but this was offset by a high
rate of transient (16%) and sustained (7%) reocclusion
during the procedure and recurrent ischaemia during the
first 24 h (17%). The clinical course was more favourable
after non-invasive therapy, with a lower incidence of
recurrent ischaemia within 24 h (3%), bleeding
complications, hypotension, and ventricular fibrillation.
Mortality at 14 days was lower in patients allocated to
non-invasive treatment (3%) than in the group allocated to
invasive treatment (7%). No difference between the
treatment groups was observed in infarct size estimated
from myocardial release of alpha-hydroxybutyrate
dehydrogenase or in left ventricular ejection fraction after
10-22 days. Since immediate PTCA does not provide
additional benefit there seems to be no need for immediate
angiography and PTCA in patients with acute myocardial
infarction treated with rTPA.
Introduction
RANDOMISED trials of thrombolytic therapy with
intracoronary streptokinase1 or intravenous streptokinase 2
have demonstrated improved survival as well as limitation of
infarct size3 and preservation of left ventricular function4 in
patients treated within 4-6 h after onset of symptoms of
acute myocardial infarction. Several groups have proposed
*Participating clinics are listed at the end of the article.
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immediate percutaneous transluminal coronary angioplasty
(PTCA) for reperfusion of the ischaemic myocardium in
addition tos or without6 thrombolytic therapy. Immediate
PTCA may open vessels that remain occluded despite
thrombolytic therapy and reduce the residual coronary
stenosis after thrombolytic therapy. The improved
bloodflow might further reduce infarct size and preserve left
ventricular function.? Finally, PTCA might reduce the
incidence of post-infarction angina, reocclusion, and
reinfarction after thrombolytic therapy. 8,9
The European Cooperative Study Group for
Recombinant Tissue-type Plasminogen Activator (rTPA)
has conducted a randomised trial to determine whether an
invasive strategy, combining thrombolysis with rTPA,
heparin, acetylsalicylic acid, and immediate PTCA, would
be superior to a non-invasive strategy of treatment with
intravenous rTPA, heparin, and acetylsalicylic acid alone.
The end-points were enzymatic infarct size, global left
ventricular function, and findings on clinical follow-up.
Patient enrolment started in May, 1986. The trial was
prematurely terminated in June, 1987, on the advice of the
data monitoring and ethical committee. This report presents
the main results of the trial.
Patients and Methods
Ten hospitals with extensive PTCA experience in six European
countries participated in the trial. Patients were admitted with a
diagnosis of suspected myocardial infarction, characterised by chest
pain of at least 30 min duration and typical changes in the
electrocardiogram: ST-segment elevation of z3 mV or greater in
two or more chest leads (V&mdash;V) and/or greater than 0-2 mV in leads
I, II, III, aVL, aVF, Vs, or V6. In addition, patients were included
with at least 0-1 mV ST-segment elevation in two leads (II, III,
aVF, Vs> V6) and at least 0-2 mV ST-segment depression in two
chest leads VcV4.
Patients younger than 71 years in whom treatment could be
started within 5 h after the onset of symptoms were included. The
usual contraindications for thrombolytic therapy were applied. 10 In
addition, patients with a previous myocardial infarction at the same
site or with previous coronary artery bypass surgery were excluded.
Patients with heart failure or shock were not excluded.
When informed consent had been obtained, intravenous
administration of rTPA was started without delay. After a 10 mg
bolus injection, 50 mg was given in the first hour, followed by 40 mg
in the next 2 h. Thus, in total 100 mg was administered in 3 h.
Single-chain rTPA (Genentech Inc, G-11044) was supplied by
Boehringer Ingelheim International GmbH. In addition to rTPA,
250 mg acetylsalicylic acid was given intravenously, plus heparin
5000 IU followed by a continuous infusion of 1000 IU/h. Patients
were allocated by telephone to either the non-invasive strategy of
treatment with intravenous rTPA, acetylsalicylic acid, and heparin
or to the invasive strategy with the same medical treatment
combined with immediate PTCA. At first a lower dose of 75-125
mg acetylsalicylic acid was given as initial treatment. As the PTCA
procedure was complicated by reocclusion in about 5 out of 7
patients allocated to invasive strategy, the initial dose of
acetylsalicylic acid was increased to 250 mg.
The protocol specified that coronary angiography was to be
performed as soon as the catheterisation laboratory was available.
Mechanical recanalisation should be attempted if the infarct-related
segment of the coronary artery appeared occluded. PTCA should
be attempted in all patients, unless the diameter stenosis of the
lesion was judged to be less than 60%. Until hospital discharge all
patients were anticoagulated with heparin, which could be replaced
by warfarin after 3 days, provided that full anticoagulation was
maintained. In addition, 75-125 mg acetylsalicylic acid was given
every other day. Beta-blockers, calcium antagonists, and nitrates
could be prescribed when indicated but were to be withdrawn the
night before late angiography.
TABLE I-BASELINE CHARACTERISTICS
Actual number of patients are shown. Continuous variables are presented as
median and 90% range. Percentages of patients in each treatment group or
ranges are shown in parentheses.
Infarct size was estimated from serial alpha-hydroxybutyrate
dehydrogenase (HBDH) determinations by the core laboratory for
enzyme determination.11,12 Blood samples were taken at admission
and at 12, 24, 36, 48, 72, and 96 h. Enzymatic infarct size was
estimated by the cumulative quantity of HBDH released by the
heart per litre plasma in 72 h (Q72).
Coronary arteriography and ventriculography were performed
before hospital discharge. To ensure comparability, each hospital
chose a time window in which late angiography was scheduled:
10-14, 12-16, 14-18, 16-20, or 18-22 days after admission. Left
ventricular ejection fraction was computed by the core laboratory
for quantitative angiography. In addition to local assessment of the
coronary angiograms, both acute and late angiograms were centrally
assessed by members of the angiography assessment group. In
patients who underwent immediate PTCA, all intracoronary
manipulations, including further dilatations with a larger size
balloon in case of reocclusion, were considered to be part of the same
PTCA procedure until the guiding catheter was withdrawn.
Further procedures that were performed after withdrawal of the
guiding catheter are reported as new interventions (re-PTCA).
Two methods of grading of coronary angiograms were applied-the
grades of diameter stenosis as previously used by the European
Cooperative Study Group10 and the TIMI perfusion score:"
Grades of Stenosis
Grades of Perfusion
0 = non-perfusion
1 = penetration with minimal perfusion (contrast fails to opacify
entire coronary bed distal to the stenosis for the duration of the
cine run)
2 = partial perfusion (contrast opacifies the entire coronary bed
distal to the stenosis. However, the rate of entry and/or
clearance is slower in coronary bed distal to the obstruction
than in comparable areas not perfused by the infarct related
vessel)
3 = complete perfusion (filling and clearance of contrast as rapid
in coronary bed distal to stenosis as in other coronary beds)
Both the core laboratory for enzyme determination and the core
laboratory for quantitative angiography were unaware of the
treatment allocation.
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Results
367 patients were evaluated. The median number of
patients per hospital was 34, ranging from 13 to 78 patients.
184 patients were allocated to non-invasive treatment and
183 to rTPA followed by immediate angiography and
PTCA. 1 additional patient had been allocated to non-
invasive therapy but has been excluded from analysis
because treatment allocation as given by telephone was not
correctly interpreted by the local investigator and immediate
PTCA was performed. This patient had an uneventful
follow-up. Baseline characteristics were similar in the two
treatment groups, except that the non-invasive group had 1
patient with severe cardiac failure on admission and the
invasive group 7 patients, and mild heart failure on
admission was more frequent in the non-invasive group
(table l). Immediate angiography was performed in 180
patients (fig 1). Angiography was not performed in 1 patient
who died from shock, in 1 patient because of withdrawal of
consent, and in 1 patient for technical reasons. The delay
between onset of symptoms and rTPA infusion ranged from
30 to 294 min, median 156 min, and the delay between
infusion and angiography ranged from 6 to 165 min, median
42 min.
Fig I-Results of angiography and PTCA in 180 patients allocated to
invasive treatment who underwent immediate angiography.
Vessels were classified as patent (0 =stenosis grades 0-3) or occluded
(. = stenosis grades 4-5). In 2 patients no angiogram was available after
attempted PTCA.
Fig 2-Patency of infarct related vessel (stenosis grades 0-3) in
relation to interval between start of rTPA infusion and
angiography.
The four large dots indicate percentage of patients with a patent vessel
when angiography was performed within 30, 30-60, 60-90, and later than 90
min after start of infusion. A logistic regression model was used to estimate the
relation between the duration of rTPA infusion and patency. The result of
this analysis is presented by the closed line, and its 95% confidence intervals
by the dotted lines. Estimated patency at 90 min was 89%. In 4 patients the
exact delay was uncertain. In the four groups patency was 15/44, 51/81,25/37,
and 14/14.
TABLE II-CLINICAL COURSE AND FOLLOW UP
Actual number of patients with an event after allocation are presented;
percentages of patients in each treatment group are shown in parentheses.
Recurrent ischaemia after 24 h represents patients without reinfarction.
Numbers given for status at 3-month follow-up are cumulative. *CT scan: no
bleeding.
Immediate Angiography
In patients allocated to invasive therapy, patency (defined
as stenosis grades 0-3) was related to the delay between onset
of rTPA infusion and angiography as shown in fig 2.
Complete occlusion (grade 5) was observed in 42 patients
and subtotal occlusion without complete filling of the distal
vessel (grade 4) in 30 patients (fig 3a). PTCA was attempted
in 168 patients. No immediate PTCA was done in 8 patients
who did not have significant lumen narrowing, in 3 patients
in whom the anatomy was judged unsuitable for PTCA (1
left main equivalent, 1 severe 3-vessel disease, and 1 old
occlusion in the anterior descending artery with retrograde
filling by the right coronary artery), and in 1 patient in whom
the infarct-related vessel could not be identified (fig 1).
Immediate PTCA in this study appeared to be more
troublesome than elective PTCA. The number of balloon
inflations ranged from 1 to 15, median 4, with a total
inflation time between 30 and 885 s, median 180. In 5
patients the lesion could not be crossed with guidewire or
balloon. In 32 patients more than one stenosis was dilated.
At the end of intervention, central angiographic assessment
revealed an occluded vessel (grades 4 and 5) in 17 patients
and less than 50% stenosis (grades 0 and 1) of the
infarct-related segment in 103 patients (fig 3). Before the
initial acetylsalicylic acid dose was increased to 250 mg
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Fig 3-Grades of stenosis (a) and perfusion (b) of infarct-related
vessel before and after PTCA and after 10-22 days in patients
allocated to invasive (IN) and non-invasive (non-IN) therapy.
Unknown = patients in whom the infarct-related segment (a) or artery (b)
could not be identified in the angiogram. The number of patients with
angiography is given under each bar: numbers next to the bars represent the
number of patients in that particular subgroup.
intravenously, transient reocclusion during intervention
occurred in 4 out of 7 patients and permanent reocclusion in
1. After increasing the acetylsalicylic acid dose, transient
reocclusion during intervention occurred in 22 and per-
manent reocclusion in 12 patients in whom PTCA was
attempted. Additional intracoronary streptokinase was
given in 2 patients with transient reocclusion and in 1 patient
because of recurrent stenosis. In 2 patients an initially patent
infarct-related segment was found to be occluded after
completion of the PTCA procedure. In 1 other patient
reocclusion occurred during coronary angiography before
PTCA. Subsequent PTCA was not successful.
Clinical Course
The clinical course is summarised in table 11. Overall, the
outcome was more favourable in patients with non-invasive
therapy. Differences between the treatment groups were
equally distributed over the participating clinics, and not
dependent on infarct location at admission. Mortality at 14
days and at three months was low (3%) in patients allocated
to non-invasive strategy. 1 patient in this group was
resuscitated during rTPA infusion (table III). He had
intraperitoneal bleeding from a liver haematoma on day 2
and died on day 3 after reinfarction and shock. In patients
allocated to invasive therapy, 14 day mortality was 7%. 4 of
the 7 patients in this group admitted with severe heart failure
or shock died. Two deaths after immediate PTCA were
associated with bleeding complications, one of them in a
patient who died from intraperitoneal bleeding, probably
caused by trauma before hospital admission.
Recurrent ischaemia within 24 h was observed in 17% of
patients with immediate PTCA and in 3% of patients
allocated to non-invasive therapy. In the latter group
exacerbation or recurrence of chest pain was recorded in 1
patient, chest pain with ST-segment elevation in 4 patients,
and ST-elevation without chest pain in 1 patient. After
PTCA these figures were, 4, 19, and 8, respectively.
Episodes of hypotension and ventricular fibrillation were
more frequent after PTCA.
Bleeding complications were more prominent after
immediate PTCA, mostly as a result of arterial puncture and
the catheterisation procedure. 1 patient in the PTCA group
underwent surgery for a retroperitoneal haematoma
after angiography, and 2 patients survived after
pericardiocentesis for cardiac tamponade. In 1 patient this
was related to perforation by a pacemaker electrode, in the
other there was no apparent trauma. In the group allocated
to non-invasive treatment, 1 patient survived after
pericardiocentesis for cardiac tamponade. The greater
incidence of bleeding complications after attempted PTCA
is also apparent from the greater drop in haematocrit in these
patients (44 SD 4% at admission and 37 SD 5% after 72 h)
in comparison with those treated non-invasively (44 SD 4%
and 40 SD 5%, respectively), and from the greater need for
blood transfusions.
Enzymatic Infarct Size
Complete blood sample series for determination of
enzymatic infarct size by the core laboratory were obtained
in 309 patients (84%). HBDH-Q72 could be estimated from
series of HBDH measurements obtained up to 36 or 48 h in
18 patients, and from a single HBDH plasma level between
24 and 96 h after onset of symptoms in 25 patients. Local
determinations of aspartate aminotransferase (ASAT) or
HBDH could be employed to estimate HBDH-Q72 in 7
patients. Thus, enzymatic infarct size could be assessed in
359 patients (98%). In 7 patients HBDH data were not
available because of early death and in 1 patient because of
early bypass surgery. Enzymatic infarct size did not differ
between the non-invasive group (median 665 U/1, 90%
range 32-2022 U/1) and the invasive group (median 706 U/1,
90% range 115-1914 U/1). Similar results were. obtained
when only complete sample series from 309 patients were
used.
Late Angiography
The effect of immediate PTCA on the status of the
infarct-related segment after 10-22 days is best described by
the grade of residual stenosis (fig 3a). An occluded vessel
(grades 4 and 5) was observed in 20 patients without PTCA
and in 23 patients with immediate PTCA. On the other
hand, stenoses of less than 50% diameter were observed
more frequently in patients allocated to invasive therapy
(n = 106) than in the other group (n = 25). These differences
were not apparent if the TIMI perfusion score was applied,
as shown in fig 3b. Complete perfusion (TIMI grade 3) was
observed in 138 patients after non-invasive initial therapy
and in 130 patients after immediate PTCA.
Left ventricular angiography was performed in 333
patients between days 10 and 22. Missing angiograms were
due to patient death (n = 17), patient refusal (n = 6),
coronary bypass surgery (n = 3), very poor ventricular
function (n = 2), ventricular tachycardia (n = 1), and re-
infarction (n = 1), and in 4 cases to clinical, non-cardiac
reasons. Quantitative analysis was performed in 291
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TABLE II I-EARLY AND LATE MORTALITY
Baseline data, results of angiography and PTCA, when performed, as well as time and cause of death are given. Stenosis grades before and after PTCA as centrally
assessed are presented. IRV = infarct-related vessel; A = anterior, I = inferior; * = shock at admission; LAD = left anterior descending artery; RCA = right
coronary artery; LCX = left circumflex artery; VF = ventricular fibrillation; CABG = coronary artery bypass grafting; h = hours after allocation; d = days after
allocation.
angiograms of adequate quality. There were no differences
in left ventricular ejection fraction between patients
allocated to non-invasive therapy and those allocated to
invasive therapy (median 51%,90% range 29-65%, versus
median 51%, 90% range 31-66%).
Discussion
Contrary to what was expected when the study was
designed, thrombolytic therapy combined with immediate
PTCA did not appear to be superior to early non-invasive
treatment with intravenous rTPA, heparin, and acetyl-
salicylic acid in acute myocardial infarction. Immediate
PTCA was effective in increasing the number of patients
with a patent infarct-related vessel and improved perfusion
as visualised during angiography (fig 3). However, in the
setting in which it was studied, PTCA was associated with a
high rate of early reocclusion and/or early recurrent
ischaemia. Also, immediate PTCA did not further reduce
enzymatic infarct size or improve global left ventricular
function when compared with non-invasive treatment.
Finally, a complicated clinical course occurred more
frequently after PTCA and 3-month mortality was higher
than after non-invasive therapy.
The present study was planned to include a total of 400
patients. However, when the data monitoring and ethical
committee reviewed the data in June 1987, it became
apparent that immediate PTCA in this setting was not
beneficial and might even be detrimental in some cases. At
that time mortality was 6 out of 171 patients allocated to
non-invasive therapy and 11 out of 173 patients allocated to
invasive therapy, while cardiovascular and bleeding
complications were also more frequent in the latter group.
Enzymatic infarct size had been determined in 165 patients
and left ventricular ejection fraction in 110 patients. Median
values in the non-invasive and invasive group were 730 U/1
versus 911 U/1 for HBDH-Q72 and 53% versus 47% for left
ventricular ejection fraction. Therefore, patient intake was
terminated by the steering committee as of June 27, 1987.
In patients allocated to invasive strategy who underwent
angiography 42 min after the start of rTPA infusion
(median), the infarct-related segment was patent (stenosis
grades 0-3) in 59%. It should be appreciated that in most
other studies8 10,13,14 patency rates were reported after 90
minutes’ infusion of rTPA. Fig 2 shows that patency is
achieved gradually during rTPA administration and ranges
from 34% in patients studied within 30 min to 100% in
patients studied between 90 and 165 min from the start of
infusion. Patency at 90 min, estimated by a logistic
regression model, was 89%.
Recurrent ischaemia and/or reinfarction within 14 days
was observed in 15 % of patients after non-invasive therapy.
Similar results were obtained in the TAMI Study, where
recurrent ischaemia and/or reinfarction was observed in
17% of patients with a patent vessel without immediate
PTCA.14 It should be appreciated that the clinical observa-
tion of recurrent ischaemia or reinfarction does not neces-
sarily coincide with angiographic reocclusion. For example,
in the TAMI study reocclusion was observed in only 6 out of
17 patients who underwent angiography for recurrent
ischaemia.14 These observations confirm the results from an
earlier study by the European Cooperative Study Group in
which reocclusion occurred in 7% of 73 patients 6-24 h after
double-chain rTP A.15 Thus reocclusion after thrombolysis
with rTPA occurs less frequently than indicated by earlier
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studies in a small number of patients treated with a relatively
low dose of double-chain rTPA.16
Immediate PTCA in patients with acute myocardial
infarction was introduced as an extension of intracoronary
thrombolytic therapy with streptokinase.5 In selected
patients, PTCA after intracoronary streptokinase has been
reported to reduce the risk of reocclusion and mortality. 5,6 In
a randomised trial, Erbel et al 17 compared treatment with
intracoronary streptokinase with and without immediate
PTCA in 162 patients. These workers report that PTCA
reduced the reocclusion rate at 4 weeks from 14 out of 71
patients with a patent vessel without PTCA (20%) to 10 out
of 71 patients (14%) after PTCA, while a trend towards
lower mortality in patients with immediate PTCA was also
observed. 17-19 Thus, the question arises whether the
response to angioplasty in patients treated with
streptokinase differs from that in patients treated with
rTPA. The higher tendency to reocclude in the latter group
might be related in part to the "thrombus specificity" of
rTPA. Remnants of thrombus material, together with the
endothelial trauma caused by PTCA and subintimal
bleeding,20,21- can then be held responsible for the tendency
to thrombosis in patients treated with rTPA, despite
concomitant treatment with acetylsalicylic acid and heparin,
while early rethrombosis after PTCA in patients treated
with streptokinase may be prevented by the depletion of
fibrinogen and other coagulation factors due to
streptokinase. On the other hand, it is possible that
differences between studies of PTCA in combination with
streptokinase or rTPA are merely due to patient selection
and small sample sizes.
The clinical course in the present study was less
favourable in patients allocated to immediate PTCA. The
higher mortality in the invasive group may be due in part to
the greater number of patients with severe heart failure or
shock at admission, of whom 4 died, and to the high
incidence of reocclusion during or after immediate PTCA.
The latter factor can also explain the higher incidence of
hypotension and ventricular fibrillation. The higher inci-
dence of bleeding complications was related to arterial
puncture for angiography and PTCA. The observations in
the present trial are similar to those reported from the
TAMI14 trial which likewise showed a trend towards higher
mortality without improvement in global or regional
ejection fraction. It should be noted, however, that the
design of these two studies was different. In TAMI all
patients underwent acute angiography and only those with a
patent vessel, suitable for PTCA, were randomised (197 out
of 386 patients). In the present study acute angiography was
performed only in patients randomised to invasive strategy
and PTCA was attempted in 92% of these. TAMI
answered the question whether PTCA would be beneficial
in a selected subgroup of patients who underwent angiogra-
phy during thrombolytic therapy with intravenous rTPA.
The European Cooperative Study Group investigated
whether an invasive strategy, including angiography and
immediate PTCA, would be superior to non-invasive
intravenous thrombolytic therapy with rTPA. These
differences notwithstanding, both studies indicate that
immediate PTCA after intravenous rTPA in combination
with acetylsalicylic acid and heparin should be avoided.
The present study was not designed to demonstrate the
effect of thrombolysis with intravenous rTPA per se. The
value of thrombolytic therapy in selected patients with acute
myocardial infarction has been shown by randomised trials
with intracoronary and/or intravenous streptokinase.l-4
Patient selection criteria in the present trial were similar to
those of the trial conducted by the Interuniversity Cardio-
logy Institute in the Netherlands.1 Hospital mortality in
conventionally treated patients in that study was 10%, and
6% in patients allocated to intracoronary streptokinase. In
the present trial 14-day mortality in patients treated
non-invasively was even lower-3%. Were these findings to
be confirmed by ongoing trials comparing the effect of
intravenous rTPA and placebo on enzymatic infarct size,
left ventricular function, and mortality, treatment with
rTPA should certainly be recommended in selected
patients. An invasive strategy of treatment with rTPA,
acetylsalicylic acid, and heparin, in combination with,
immediate angiography and PTCA has no additional
benefit. Delayed angiography, PTCA, or bypass surgery
might be offered to patients with new episodes of myocardial
ischaemia.
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CORONARY THROMBOLYSIS AND
MYOCARDIAL SALVAGE BY TISSUE
PLASMINOGEN ACTIVATOR GIVEN UP TO 4
HOURS AFTER ONSET OF MYOCARDIAL
INFARCTION
NATIONAL HEART FOUNDATION OF AUSTRALIA
CORONARY THROMBOLYSIS GROUP *
Summary 144 patients presenting within 4 h of onset
of myocardial infarction were randomised
to receive either 100 mg of single-strand recombinant tissue
plasminogen activator (rTPA) in 3 h (n=73) or placebo
infused at the same rate (n=71). All patients were given
heparin 5000 units before the infusion and heparin was
continued, initially at 1000 units per hour, after the infusion.
Minor bleeding was more frequent in the rTPA recipients,
and during subsequent anticoagulant therapy there were
three clinically significant bleeding episodes in this group.
Patency of the infarct-related coronary artery was
determined by coronary angiography about one week
post-infarction, 125 angiograms being assessable. The
infarct-related artery was patent in 70% of patients who
received rTPA and in 41% of those who did not
(p = 0&middot;0015). In the 103 patients who had assessable contrast
ventriculograms, the global ejection fractions were 57&middot;7%
and 51&middot;7%, respectively (p=0&middot;04). The difference in
ventricular function was largest in patients with anterior
infarction (52&middot;7% versus 40&middot;0%, p=0&middot;02). The magnitude
of these changes suggests an improvement in ejection
fraction of 12% overall and about 30% in patients with
anterior infarction.
Introduction
CORONARY thrombolysis with an intravenous fibrinolytic
agent has been shown to be a feasible and effective therapy
for patients presenting early after acute myocardial
infarction. 1-5 Recombinant tissue plasminogen activator
(rTPA) has properties of clot selectivity and lack of
antigenicity which render it suitable for use in these
circumstances.6,7 Initial clinical experience in Europe and
the United States showed that it is a highly effective
thrombolytic agent achieving coronary recanalisation in up
*Participating centres are listed at the end of the article.
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to 70% of cases.8-H To date there is no certainty that the
reperfusion so achieved will improve left ventricular
function and it is not clear whether the coronary artery will
remain patent for long enough to allow elective management
of the residual stenosis. To answer these questions we
designed a trial to assess the effect of rTPA on ventricular
function and coronary patency one week after intravenous
administration. The timing of cardiac catheterisation was
chosen to avoid the phase of early ventricular dysfunction
that persists after coronary perfusion12 while allowing
examination of the results before the patient left hospital (so
that coronary revascularisation, if indicated, could be
planned).
The trial was a randomised double-blind, placebo-
controlled, multicentre study in five Australian teaching
hospitals, conducted between May, 1986, and August, 1987.
Patients and Methods
Patient Selection
Patients aged 75 years or less, with suspected new or recurrent
myocardial infarction, were considered for the trial if they presented
to hospital within 4 h of symptoms, if they had cardiac pain of
typical character and location, and if the electrocardiogram showed
ST segment elevation in two or more leads ( > 2 mm in suspected
anterior infarction or > 1 mm in suspected inferior infarction).
Patients were excluded if there was a contraindication to
thrombolytic therapy. After informed consent patients were
randomised to active or placebo groups with separate strata for
patients < 2 h from onset of pain and recurrent infarction.
rTPA and Heparin Infusion
The active drug was recombinant tissue plasminogen activator
produced by a cell suspension culture process that generates
predominantly the single-chain product (manufactured by
Genetech and supplied by Boehringer Ingelheim Pty Ltd). All
patients received intravenous heparin, 5000 units, immediately
before the rTPA/placebo infusion. Patients in the active group
received a bolus injection of 10 mg of rTPA followed by 50 mg over
the next hour and 40 mg over the subsequent 2 h. Patients in the
placebo group received an inactive infusion of normal saline at the
same rate. After completion of the infusion, heparin was begun at a
rate of 1000 units per hour and monitored regularly to achieve
therapeutic heparin activity.
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